FDA Grants Priority Review to Teva's New Tourette Syndrome Treatment Ecopipam

Key Facts

In a move that strengthens the company's position in the neuroscience sector, the U.S. Food and Drug Administration (FDA) has accepted Teva Pharmaceutical's New Drug Application for ecopipam. The agency granted priority review status to the investigational therapy, which is designed to treat pediatric Tourette syndrome. According to reports, a PDUFA action date for the regulatory decision has been targeted for late in the first quarter of 2027.

This acceptance aligns with Teva's 'Pivot to Growth' strategy, focusing on expanding its innovative medicine pipeline. The application is supported by clinical data positioning ecopipam as a potential first-in-class therapy. Per market data, TEVA shares closed at $36.58 on August 18, 2026, having reached a daily high of $37.25 during that session.

Investors are now monitoring the regulatory timeline leading into 2027, as the drug represents a long-term catalyst for revenue growth in the neuroscience division. Based on price levels as of the August 18, 2026 close, the stock maintains support near its daily low of $36.34 while the market awaits further clinical updates or strategic milestones from the company.